+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 120Years
MALE
ID07686380

Phase 2 Study of IL-15 Superagonist N-803 With or Without ETBX-071 Vaccine in Men With Biochemically Recurrent Prostate Cancer Previously Treated With Stereotactic Body Radiation Therapy

Led by National Cancer Institute (NCI) · Updated on 2026-10-06

65

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying men with biochemically recurrent prostate cancer BCR, a condition where prostate-specific antigen PSA levels rise after surgery or radiation. This trial evaluates the effects of an IL-15 superagonist drug called N-803 alone or combined with an adenoviral-based vaccine called ETBX-071. The goal is to see if these treatments can reduce PSA levels in men who previously received targeted stereotactic body radiation therapy SBRT. Participants will be randomly assigned to one of two groups one receiving N-803 alone and the other receiving both N-803 and the ETBX-071 vaccine. Both treatments are given by subcutaneous injection on the first day of each 21-day cycle, for a total of eight cycles over six months. Imaging scans, including three tumor scans and PET scans, along with blood tests, will be conducted before, during, and after treatment. During the study, participants will undergo physical exams, heart and kidney function tests, and regular blood tests. Follow-up visits will occur every 4 to 8 weeks for up to five years, with PET scans every six months. Researchers will measure treatment efficacy by tracking PSA changes and imaging results, monitor safety throughout the treatment cycles, and record long-term outcomes related to PSA progression and response duration.

CONDITIONS

Brief Title

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

Research Team

A

Amy R Hankin, P.A.-C

M

Melissa L Abel, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here